ClinicalTrials.gg
CompletedNCT04514796Updated May 26, 2021

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

A Phase 1 interventional study of Adalimumab in Healthy, sponsored by Samsung Bioepis Co., Ltd.. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-26.

Sponsored by Samsung Bioepis Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This study is to evaluate to compare the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of SB5 in healthy male subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Samsung Bioepis Co., Ltd. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male, aged 18-55 years (inclusive).
  2. A body weight between 65.0-90.0 kg (inclusive) and a between 20.0-29.9 kg/m2 (inclusive)
  3. 12-lead results without abnormal.
  4. Systolic blood pressure ≤ 140 and ≥ 90 mmHg, diastolic blood pressure ≤ 90 and ≥ 50 mmHg and pulse rate ≥ 45 and ≤ 90 beats per minute or assessed as not clinically significant.
  5. Physical examination results without clinically significant abnormal findings.
  6. Clinical laboratory results within the normal range or outside the normal range but assessed as not clinically significant.
  7. Male subjects who did not have surgical sterilisation must be willing to abstain from sexual intercourse or willing to use a condom in addition to having their female partner use another form of such as an intra-uterine device, oral contraceptive, injectable progesterone, sub-dermal implant, or a tubal ligation unless their partners are infertile from the time of the product (IP) administration until 5 months after the IP administration.
  8. Willing and able to comply with study procedures including lifestyle consideration.
  9. Able to provide written prior to any study procedures.

Exclusion criteria

Exclusion Criteria

  1. A history and/or current presence of atopic, or allergic, also including known or suspected clinically relevant drug hypersensitivity to adalimumab or to any of the .
  2. A history of and/or current clinically significant gastrointestinal, renal, hepatic, haematological, pulmonary, neurologic, psychiatric, drug or alcohol abuse, or allergic disease excluding mild asymptotic seasonal allergies.
  3. Either active or latent tuberculosis (TB) or a history of TB.
  4. A history of invasive systemic fungal infections or other opportunistic infections.
  5. A history of any systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process within 180 days prior to Randomisation.
  6. A sign of ongoing or chronic inflammation process defined as high blood concentration of C reactive protein (> 1.5 times the ).
  7. A history of serious infection (associated with hospitalisation and/or which required intravenous antibiotics) within 180 days prior to Randomisation.
  8. Previously been treated with adalimumab.
  9. Previously been exposed to a monoclonal antibody or fusion protein (other than adalimumab) within 180 days prior to Randomisation and/or there is a confirmed evidence or clinical suspicion of immunogenicity from previous exposure to a monoclonal antibody or fusion protein.
  10. Previously been exposed to an agent or biological agent (any other than a monoclonal antibody or fusion protein) within 120 days prior to Randomisation.
  11. Received (s) within 30 days prior to Randomisation or who will require live vaccine(s) during the study period.
  12. A history of and/or current cardiac disease defined as one of the following:

    1. Personal or family history of prolonged syndrome or Torsade de Pointes.
    2. QT interval corrected by Fridericia's formulas > 450 msec or PR interval outside the range 120 to 220 msec.
    3. Signs and symptoms or any history suggestive for heart failure.
    4. Any other cardiac abnormalities or conditions assessed as clinically significant.
  13. Impaired liver, pancreas and biliary system as determined by one of the following:

    1. Serum and/or aspartate transaminase ≥ 1.5 times the upper limit of normal.
    2. Gallbladder or bile duct disease classified as clinically significant.
    3. Acute or chronic pancreatitis.
    4. A positive virus antibody test or virus surface antigen test, or signs for active or chronic hepatitis B.
    5. Hepatic disease classified as clinically significant.
  14. A positive test result for , or have a history of immunodeficiency.
  15. A history of (including lymphoma and leukaemia) other than a successfully treated non- cutaneous squamous cell carcinoma, basal cell carcinoma or localised carcinoma.
  16. Had surgery within 90 days prior to Randomisation, and/or who plan to have an operation during the study period.
  17. A history and/or current presence of an illness within 14 days prior to Randomisation that is classified as clinically significant.
  18. Have a history of and/or current Coronavirus Disease-19 (COVID-19) defined as one of the following:

    1. Positive test result for COVID-19 confirmed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using real-time reverse transcriptase polymerase chain reaction (RT-PCR) at Day -1.
    2. Signs and symptoms consistent with COVID-19 30 days prior to Randomisation.
    3. Have had a positive test result for COVID-19 confirmed by SARS-CoV-2 detection using real-time RT-PCR.
    4. Had severe course of COVID-19.
  19. Smoked more than 10 cigarettes, 2 cigars or 2 pipes per day within 90 days prior to Screening.
  20. Regular consumption of alcoholic beverages that exceeds 14 units.
  21. A positive urinary drug screening result.
  22. Any prescription medicine or over-the-counter medicines (except paracetamol) that might have an effect on the objectives of the study in the opinion of the Investigator, within 30 days prior to Randomisation.
  23. Donated > 100 mL blood or plasma within 28 days prior to Randomisation.
  24. Participated in another study with an drug within 60 days prior to Randomisation or are currently participating in or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluations in this clinical study.
  25. Subjects who, in the opinion of the Investigator, are not likely to complete the study for whatever reason.
  26. Subject who is the Investigator or any sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the clinical study.
  27. Vulnerable subjects.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    40 mg/0.4 mL of SB5

    100 mg/mL of SB5

    Drug: Adalimumab

  • Active comparator
    40 mg/0.8 mL of SB5

    50 mg/mL of SB5

    Drug: Adalimumab

Interventions

  • SB5 (adalimumab), 40 mg, single-dose

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under the concentration-time curve from time zero to infinity

    Time frame: Day 1 to Day 57

  2. Cmax

    Maximum serum concentration

    Time frame: Day 1 to Day 57

Secondary outcomes

  1. AUClast

    Area under the concentration-time curve from time zero to the last quantifiable concentration

    Time frame: Day 1 to Day 57

  2. Tmax

    Time to reach Cmax

    Time frame: Day 1 to Day 57

  3. Vz/F

    Apparent volume of distribution during the terminal phase

    Time frame: Day 1 to Day 57

  4. λz

    Terminal rate constant

    Time frame: Day 1 to Day 57

  5. t1/2

    Terminal half-life

    Time frame: Day 1 to Day 57

  6. CL/F

    Apparent total body clearance

    Time frame: Day 1 to Day 57

  7. %AUCextrap

    Percentage of AUCinf due to extrapolation from time of last measurable concentration (Tlast) to infinity

    Time frame: Day 1 to Day 57

  8. Incidence of treatment-emergent adverse events (TEAEs)

    Experience at least 1 TEAE

    Time frame: Day 1 to Day 57

  9. Incidence of serious adverse events (SAEs)

    Experience at least 1 SAE

    Time frame: Day 1 to Day 57

  10. Incidence of anti-drug antibodies (ADAs)

    Incidence of ADAs to adalimumab

    Time frame: Day 1 to Day 57

  11. Incidence of neutralising antibodies (NAbs)

    Incidence of NAbs to adalimumab

    Time frame: Day 1 to Day 57

07

Study locations

1 site
  • Parexel International GmbH, Early Phase Clinical Unit Berlin
    Berlin, 14050, Germany
08

References and documents

Publications

  • Ahn SS, Lee M, Baek Y, Lee S. A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar). Rheumatol Ther. 2022 Aug;9(4):1157-1169. doi: 10.1007/s40744-022-00471-8. Epub 2022 Jul 1. PubMed 35776269 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in May 2021, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 17, 2020
StartActual
Aug 13, 2020
Primary completionActual
May 15, 2021
CompletionActual
May 15, 2021
Last update
May 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04514796
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Aug 13, 2020
Primary completion
May 15, 2021
Completion
May 15, 2021
Last update
May 26, 2021

Study contacts

Thomas Köernicke, MD
principal investigator · Parexel International GmbH, Early Phase Clinical Unit Berlin

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion